Current opinion in ophthalmology (Curr Opin Ophthalmol)

Publisher: Lippincott, Williams & Wilkins

Journal description

Topics Covered: Cataract Surgery and Lens Implantation; Glaucoma; Retina and Vitreous Disorders; Corneal and External Disorders and Refractive Surgery; Strabismus; Oculoplastic and Orbital Surgery; Neuro-ophthalmology; Ocular Manifestations of Systemic Disease.

Current impact factor: 2.50

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.5
2013 Impact Factor 2.638
2012 Impact Factor 2.557
2011 Impact Factor 2.647
2010 Impact Factor 2.429
2009 Impact Factor 2.49
2008 Impact Factor 2.958

Impact factor over time

Impact factor

Additional details

5-year impact 2.69
Cited half-life 6.80
Immediacy index 0.42
Eigenfactor 0.01
Article influence 0.89
Website Current Opinion in Ophthalmology website
Other titles Current opinion in ophthalmology (Online), Current opinion in ophthalmology
ISSN 1531-7021
OCLC 36903873
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Lippincott, Williams & Wilkins

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • Pre-print must be removed upon acceptance for publication
    • Post-print may be deposited in personal website or institutional repository
    • Publisher's version/PDF cannot be used
    • Must include statement that it is not the final published version
    • Published source must be acknowledged with full citation
    • Set statement to accompany deposit
    • Must link to publisher version
    • NIH authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 12 months embargo (see policy for details)
    • Wellcome Trust and HHMI authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 6 months embargo (see policy for details)
    • Publisher last reviewed on 19/03/2015
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To review important eye movement disorders in multiple sclerosis (MS) and update the ophthalmologist on disease-modifying therapies in MS, from the perspective of expert neurologists. Recent findings: A large study confirmed that eye movement abnormalities in MS can be commonly identified by bedside examination. Identifying such ocular motility disturbances can assist in the diagnosis and prognosis for patients with MS. Articles published on such agents as oral teriflunomide and the biologics, natalizumab and alemtuzumab, have defined emerging roles of these treatments in the management of MS. Summary: Many patients with MS suffer from isolated or a combination of eye movement disorders. Understanding their ocular motility disturbance patterns can help diagnose MS and correlate with the progression of MS. Exciting advances in MS disease-modifying treatments have been developed. Patients have more options than ever before of injectable, infusion and oral therapies. The therapeutic efficacy in lowering relapse rates is counterbalanced by these drugs' side-effects.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000211
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The present review summarizes the body of literature concerning the medical and surgical treatment of thyroid eye disease (TED) from 1 January 2014 through 30 March 2015. Recent findings: Corticosteroids continue to be the primary medical therapy for TED. Recent research has offered insight into potential differences between oral corticosteroid and intravenous corticosteroid treatment regimens in terms of efficacy and side-effect profiles. Steroid-sparing medications, for example, rituximab and others, are an area of active study. There has been renewed interest in the role of radiation therapy as a nonmedical treatment for TED with some promising data. The use of balanced orbital decompression techniques have become popular, although the data regarding postoperative diplopia are mixed, and 'fat decompression' offers an alternative or an augmentation to bony decompression. Stereotactic image guidance is a useful adjunct to orbital decompression surgery. Summary: TED continues to be a difficult condition for the patient to cope with and for the clinician to treat, and recent research builds on the present foundation of knowledge and treatments, but unfortunately does not offer paradigm-shifting information at the present time.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000203
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Giant cell arteritis (GCA) remains a potentially blinding inflammatory vasculitis of the elderly. Because prolonged doses of corticosteroids remain the best established treatment, side-effects during treatment are common and potentially serious. This review addresses the challenges clinicians face in managing this disease. Recent findings: High-dose corticosteroids with slow tapering and close monitoring are the mainstay of treatment. Investigations into adjunctive treatment have yet to establish other agents as beneficial, but further research is ongoing with some promising results. Summary: GCA represents a challenging illness to clinicians because of its potential for causing blindness and the need for prolonged high doses of corticosteroids with their many complications.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000201
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: IgG4-related disease (IgG4-RD) is a systemic process that can cause significant orbital disease. It can affect both sexes and all ages, with irreversible consequences if left untreated. Diagnosis is currently based upon a combination of clinical and imaging evidence of tissue swelling or mass, serum evidence of elevated IgG4 levels and histopathologic evidence of inappropriate IgG4 presence. The cause of IgG4-RD is as of yet unclear; this lack of understanding and the dearth of prospective studies have limited our ability to manage patients effectively. In this review, we discuss the most recent published evidence regarding best-practice management of IgG4-related orbital disease. Recent findings: Recent literature remains retrospective, and has focused on the use of corticosteroid therapy as a first-line treatment. Rituximab infusions have also received significant attention, among other second-line agents. Radiation therapy has been reported to be effective. Long-term monitoring for relapse, involvement of other organ systems and potential neoplastic transformation is required. Summary: The management of orbital IgG4-RD will gain from more targeted therapy in the future as the underlying cause is better understood. In the meantime, randomized, controlled trials of varying treatment regimens would be of benefit.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000204
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common cause of an acute optic neuropathy over the age 50 with an annual incidence of 2-10/100 000. Most patients are left with a permanent decrease in visual acuity and visual field loss. No approved treatment has conclusively reversed the process or prevented a second event that typically involves the previously unaffected eye. Many medical and surgical treatments have been proposed with conflicting results. The goal of this review is to present current data in order to permit clinicians and patients to make an educated decision about treatment. Recent findings: Recently, there has been a flurry of case reports, small clinical trials and testing in animal models of NAION for various treatments for NAION and this review attempts to present the data concisely with the authors' opinions about the reliability of the data. Summary: To date, there is no class I evidence of benefit for the treatment of NAION; however, the aphorism attributed to Carl Sagan, PhD aptly applies: 'Absence of evidence is not evidence of absence'.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000199
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Neuromyelitis optica (NMO) is an antibody-mediated inflammatory disease of the central nervous system with a predilection for the optic nerves, spinal cord and certain brain regions. It has a distinct pathogenesis relating to aquaporin-4 autoimmunity and complement-mediated injury. This knowledge has translated into targeted efforts to develop novel, disease-specific treatments. In this review, we discuss evidence supporting the use of currently available treatments for acute exacerbations and for long-term disease modification. We also discuss the risks and benefits of available and emerging immunotherapies. Recent findings: Early, accurate diagnosis of NMO with appropriate acute and long-term immunosuppressive treatment is of prime importance for the prevention of disability associated with this disease. Standard measures for the management of acute exacerbations include intravenous methylprednisolone and plasmapheresis. First-line, long-term immunotherapies for NMO include azathioprine, mycophenolate mofetil and rituximab. Three randomized controlled treatment trials evaluating these agents are currently being conducted. In addition, there are numerous emerging therapies that are based upon current understanding of the disease immunopathogenesis. Summary: NMO is an autoimmune disease that is separate from multiple sclerosis. Better understanding of its antibody and complement-dependent pathophysiology has proven to be critical for the formulation of current and future treatment strategies.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000202
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Despite recent progress, the diagnosis of primary CNS lymphoma (PCNSL) remains a challenge and is often delayed by several months. Treatment options are still debated and the prognosis of PCNSL lymphoma is poor for most patients. This review will describe recent progress and future orientations for diagnosis of PCNSL and report on the recent trends regarding therapeutic options. Recent findings: PCNSL must be suspected in cases of chronic posterior uveitis, especially in patients over 50 years old. Diagnosis is based on cytology and molecular analysis of clonality of vitreous samples. Intraocular interleukin (IL)-10 level has proved to be a valuable tool for screening purposes in case where there is a suspicion of primary vitreoretinal lymphoma. Intraocular cytokine dosage could also be a useful marker to follow the therapeutic response of patients with PCNSL. Treatment of PCNSL remains under debate. Summary: Diagnosis of PCNSL is challenging. Suspicion relies on clinical history and on IL-10 and IL-6 levels in ocular fluid samples. Definite diagnosis is based on cytology and molecular analysis of clonality. New diagnostic and prognostic markers are currently evaluated. Whether isolated vitreoretinal lymphoma should be treated locally or with systemic treatment remains highly controversial.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000213
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Many patients suffer from the ocular manifestations associated with systemic lupus erythematosus (SLE). Retinal vasculitis and optic neuritis are two of the most vision-threatening complications that can be associated with the disease. Ocular manifestations are often associated with wide-spread systemic inflammation which can be fatal. Thus, immediate recognition and treatment is vital for a positive outcome. Recent findings: There is an array of medications available to ophthalmologists for treating the ocular manifestations of SLE. Treating the underlying systemic disease is crucial, as well as treating the active ocular complications. Recently, more attention has been placed on evaluating biologic agents' efficacy in treating the systemic condition. New therapies continue to emerge that have the potential to provide benefit to patients suffering from SLE. Summary: SLE is a serious systemic condition that may first present with ocular manifestations. Thus, it is crucial for ophthalmologists to be equipped with the knowledge to detect and adequately treat the disorder to avoid vision/life-threatening complications. More research is needed to determine which therapy provides the best outcome for patients with limited side-effects.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000209
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Optic neuritis is the most common cause of optic neuropathy in young adults. High-dose intravenous corticosteroids (IVCS) were established as the standard of treatment for acute optic neuritis via the Optic Neuritis Treatment Trial (ONTT), with its first findings published more than 20 years ago. Subsequent studies have further clarified the role of corticosteroids in the treatment of acute optic neuritis. Recent findings: Recent clinical research has confirmed existing knowledge of the efficacy and limitations of corticosteroids in the treatment of optic neuritis. Recent studies have examined the role of race, route of administration and combination of IVCS with other therapies. Current evidence continues to support high-dose IVCS as the cornerstone of treatment of acute optic neuritis. Summary: High-dose IVCS are effective in hastening visual recovery in acute typical optic neuritis, but do not affect the final visual outcome. In optic neuritis patients, IVCS may delay progression to clinically definite multiple sclerosis (CDMS) at 2 years, but not at 5 or 10 years. It is reasonable to recommend high-dose IVCS for acute optic neuritis patients with significant vision loss, severe pain and/or white matter lesions on brain MRI in whom the potential for benefit outweighs the risks.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000197
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The purpose of this review was to provide an overview of current data on antibiotic prophylaxis in ocular toxoplasmosis. Recent findings: Studies showing the prophylactic effect of long-term antibiotics are discussed. Prophylaxis seems to be justified in patients with a high risk of recurrence because of antibiotic's potential side-effects. Therefore, predisposing factors leading to a higher risk of recurrence and the time period during which an antibiotic prophylaxis is most appropriate are reviewed. Finally, a patient-individualized treatment recommendation is summarized. Summary: In the current literature, two prospective, randomized case-control studies exist, which show the protective effect of an antibiotic prophylaxis. Hematologic, gastrointestinal and dermatologic complications are potential side-effects. Especially during the first year after suffering a recurrence, an antibiotic prophylaxis seems to be justified. The risk of a recurrence is inter alia influenced by the duration of the disease, the immune status of the host and the patient's age. Therefore, an antibiotic prophylaxis should be considered for patients who have recently been infected with ocular toxoplasmosis, for middle-aged and elderly patients and patients with a compromised immune system. This should be discussed with each patient individually, especially if the lesion is close to the macula.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000205
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The purpose of this review is to outline agents currently in use for the local anti-inflammatory therapy of ocular Adamantiades-Behçet's disease (ABD), as well as those in translation from the laboratory to clinical use. Recent findings: Novel formulations and innovative intraocular delivery strategies have been recently applied to treat intraocular inflammation in ABD. Summary: ABD is a chronic multisystemic vasculitic disease with the highest prevalence in the Mediterranean basin and in the Eastern region of Asia. Bilateral autoimmune uveitis, oral and genital aphthous and skin lesions are the historically described triad. ABD uveitis is chronic relapsing and often sight-threatening and, according to the actual guidelines, to limit posterior segment involvement and prevent visual impairment high-dose and long-term systemic anti-inflammatory treatment is indicated. Corticosteroids, both topically and systemically, are the most effective treatment in the acute phase. To overcome the well known side-effects of corticosteroids over the long period, steroid-sparing drugs have been systemically administered showing positive results but having limited safety profile. To potentiate the intraocular pharmacological efficacy of these molecules in refractory ABD uveitis and to circumvent the risks of systemic administration, novel topical and intravitreal formulations and innovative delivering systems have been recently developed.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000210
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: This article will discuss the management of isolated, acute cranial nerve 3,4 and 6 palsies with special focus on the role of neuroimaging in older adults based on recently published data. Recent findings: Acute cranial nerve palsies affecting the third, fourth or sixth cranial nerves in isolation or in combination with other neurological signs and symptoms can be due to a variety of causes such as ischemia, inflammation, infection and compression of the ocular motor nerves. Although neuroimaging is generally recommended in all individuals presenting with ocular motor nerve palsies that occur in association with other neurological signs and symptoms, the indications for neuroimaging in older individuals (age > 50 years) who present with acute isolated ocular motor nerve palsies are less clear and controversial. Past and recent studies have attempted to address this question. A recent prospective study found that overall 16.5% of adult patients presenting with acute ocular motor mononeuropathy had structural lesions on MRI scan and 4.6% with fourth and sixth nerve palsies and no risk factors were found to have positive MRI scans. Summary: On the basis of recently published data, we recommend contrast-enhanced MRI for all patients presenting with acute, isolated ocular motor mononeuropathies irrespective of age. Studies have clearly shown a small but significant prevalence of important findings in this group of patients thus favoring neuroimaging at the time of diagnosis.
    Current opinion in ophthalmology 09/2015; DOI:10.1097/ICU.0000000000000200
  • [Show abstract] [Hide abstract]
    ABSTRACT: Continued controversy exists regarding intermittent exotropia and its management. Although it has been studied extensively, the indication for and timing of intervention and what therapy is most efficacious remains unclear. This article reviews the most recent research and the controversies surrounding the disease classification and treatment options in the management of intermittent exotropia. Current studies are underway to uncover the natural history of the intermittent exotropia. Patching and observation are reasonable treatment options in the first 6 months of the disease presentation. As the disease progresses and nonsurgical management fails, botulinum toxin may play a role or be an alternative option in the early treatment of intermittent exotropia. Surgical treatment with orthoptic therapy may result in improved postoperative outcomes. Although significant investigations have been performed on this entity, there remains poor cohesiveness between clinical trials resulting in lack of clarity regarding when and how to treat intermittent exotropia. As the natural history of the disease is elucidated and researchers standardize their assessment of the control of the strabismus and what constitutes a successful treatment outcome, better understanding may occur to develop more efficacious remedies. Despite being less known and utilized, botulinum toxin and orthoptic therapy are options for treatment for intermittent exotropia and should be considered for appropriate patient's treatment protocol.
    Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000188
  • Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000194
  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the vast genetic and phenotypic heterogeneity seen in ocular genetic disorders, considering a patient's clinical phenotype in the context of the family history is essential. Clinicians can improve patient care by appropriately incorporating a patient's family history into their evaluation. Obtaining, reviewing, and accurately interpreting the pedigree are skills geneticists and genetic counselors possess. However, with the field of ophthalmic genetics vastly growing, it is becoming essential for ophthalmologists to understand the utility of the pedigree and develop their abilities in eliciting this information. By not considering a patient's clinical history in the context of the family history, diagnoses can be missed or inaccurate. The purpose of this review is to inform ophthalmologists on the importance of the family history and highlight how the pedigree can aid in establishing an accurate genetic diagnosis. This review also provides to ophthalmologists helpful tips on eliciting and interpreting a patient's family history.
    Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000192
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purposes of this article are to examine the literature published on achromatopsia and provide a comprehensive review of the clinical disease, genetic characteristics, and potential for therapy. Specifically, this article will describe recent advances in gene therapy in animal models, clinical features in human, and barriers to human translation. Building on prior success with adeno-associated virus (AAV) therapy in mice models for achromatopsia with mutations in the CNGB3, CNGA3, or GNAT2 genes, multiple cone-specific promoters have recently been developed and shown success in mice and nonhuman primates. A sheep CNGA3 model has also been characterized. Two clinical trials are under way: one to better characterize humans with achromatopsia and another to study a ciliary neurotrophic factor (CNTF) implant as a treatment for patients with the CNGB3 mutation. Genetic understanding and disease characterization of achromatopsia continues to evolve, as do gene therapy tools and animal models. The potential for the treatment of achromatopsia in humans with gene therapy shows great promise.
    Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000189
  • [Show abstract] [Hide abstract]
    ABSTRACT: The decision to stop or continue anticoagulants or antiplatelet therapy for oculoplastic procedures has long been a complicated and serious discussion for surgeons and their patients. Although other specialties have developed evidenced-based algorithms to guide their decision-making our subspecialty remains driven largely by anecdotal information. This article aims to get closer to an evidenced-based approach to perioperative anticoagulant and antiplatelet management. Over the last few years, new antiplatelet and anticoagulant therapies are on the market with different characteristics in terms of half-life and mechanism of action. It is imperative the contemporary surgeon be well versed in these new medications. Also, new studies have emerged from the vascular literature with specific evidenced-based recommendations for heart and stroke patients. These guidelines need to be weighed with a patient's cardiologist or neurologist. The article will review the old and new anticoagulant and antiplatelet therapies as well as the recent literature for stroke and cardiac patients to guide the oculoplastic surgeon in this nuanced decision. It will also discuss current practice patterns in light of these new therapies and medical guidelines.
    Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000187
  • [Show abstract] [Hide abstract]
    ABSTRACT: Brown syndrome is an ocular motility disorder characterized by limited volitional and passive elevation of the eye in adduction. Although originally thought because of abnormalities in the trochlea or tendon sheath (limiting the free movement of the tendon through the trochlea), recent evidence suggests that some cases of congenital Brown syndrome may be related to neurodevelopmental abnormalities of the extraocular muscles (congenital cranial dysinnervation disorders, CCDD). CCDD is a term encompassing congenital abnormalities of eye movements caused by congenital innervational abnormalities. The abnormal development of cranial nerve nuclei or abnormalities in cranial nerve axonal transport affects the development of the extraocular muscle(s). Currently, congenital fibrosis of the extraocular muscles, Duane syndrome, Moebius syndrome, Horizontal gaze palsy and progressive scoliosis, and synergistic divergence are included as CCDDs. In addition, congenial ptosis, Jaw Wink ptosis, and congenital superior oblique palsy are also included. Recently, it has been suggested that some cases of congenital Brown syndrome and congenital superior oblique paresis are related, and these entities may be part of the CCDDs spectrum. Important findings regarding the cause of congenital Brown syndrome will be reviewed.
    Current opinion in ophthalmology 07/2015; 26(5). DOI:10.1097/ICU.0000000000000191